Identification of human cytochrome P450 enzymes involved in the metabolism of IN-1130, a novel activin receptor-like kinase-5 (ALK5) inhibitor

References

• Ando Y, Fuse E, Figg WD. Thalidomide metabolism by the CYP2C subfamily. Clinical Cancer Research 2002; 8(6)1964–1973
   PubMed Web of Science ®Google Scholar
• Baranczewski P, Stańczak A, Sundberg K, Svensson R, Wallin A, Jansson J, Garberg P, Postlind H. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacological Report 2006; 58(4)453–472
   PubMed Web of Science ®Google Scholar
• Bogaards JJP, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, Van Bladeren PJ, Walther B. Determining the best animal model for human cytochrome P450 activities: A comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 2000; 30(12)1131–1152
   PubMed Web of Science ®Google Scholar
• Cashman JR. Some distinctions between flavin-containing and cytochrome P450 monooxygenases. Biochemical and Biophysical Research Communications 2005; 338(1)599–604
   PubMed Web of Science ®Google Scholar
• DaCosta Byfield S, Major C, Laping NJ, Roberts AB. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Molecular Pharmacology 2004; 65(3)744–752
   PubMed Web of Science ®Google Scholar
• Emoto C, Murase S, Iwasaki K. Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage. Xenobiotica 2006; 36(8)671–683
   PubMed Web of Science ®Google Scholar
• Guengerich FP, Parikh A, Yun CH, Kim D, Nakamura K, Notley LM, Gillam EM. What makes P450s work? Searches for answers with known and new P450s. Drug Metabolism Reviews 2000; 32(3–4)267–281
   PubMed Web of Science ®Google Scholar
• Hu YF, Tu JH, Tan ZR, Liu ZQ, Zhou G, He J, Wang D, Zhou HH. Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. Xenobiotica 2007; 37(3)315–327
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology 2002; 181–182: 447–452
   PubMed Web of Science ®Google Scholar
• Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Molecular Pharmacology 2002; 62(1)65–74
   PubMed Web of Science ®Google Scholar
• Itagaki K, Carver GT, Philpot RM. Expression and characterization of a modified flavin-containing monooxygenase 4 from humans. Journal of Biological Chemistry 1996; 271(33)20102–20107
   PubMed Web of Science ®Google Scholar
• Kim YW, Kim YK, Lee JY, Chang KT, Lee HJ, Kim DK, Sheen YY. Pharmacokinetics and tissue distribution of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide; a novel ALK5 inhibitor and a potential anti-fibrosis drug. Xenobiotica 2008; 38(3)325–339
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochimica et Biophysica Acta — General Subjects 2007; 1770(3)489–494
   PubMed Web of Science ®Google Scholar
• Koo SH, Lee EJ. Pharmacogenetics approach to therapeutics. Clinical and Experimental Pharmacology and Physiology 2006; 33(5–6)525–532
   PubMed Web of Science ®Google Scholar
• Krueger SK, Williams DE. Mammalian flavin-containing monooxygenases: Structure/function, genetic polymorphisms and role in drug metabolism. Pharmacology and Therapeutics 2005; 106: 357–387
   PubMed Web of Science ®Google Scholar
• Kumar GN, Surapaneni S. Role of drug metabolism in drug discovery and development. Medicinal Research Reviews 2001; 21(5)397–411
   PubMed Web of Science ®Google Scholar
• Lin JH. CYP induction-mediated drug interactions: In vitro assessment and clinical implications. Pharmacological Research 2006; 23(6)1089–1116
   Web of Science ®Google Scholar
• Martignoni M, Groothuis GM, De Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opinion on Drug Metabolism and Toxicology 2006; 2(6)875–894
   PubMed Web of Science ®Google Scholar
• Moon JA, Kim HT, Cho IS, Sheen YY, Kim DK. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney International 2006; 70(7)1234–1243
   PubMed Web of Science ®Google Scholar
• Moon Y, Kim SY, Ji HY, Kim YK, Chae HJ, Chae SW, Lee HS. Characterization of cytochrome P450s mediating ipriflavone metabolism in human liver microsomes. Xenobiotica 2007; 37(3)246–259
   PubMed Web of Science ®Google Scholar
• Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O’Connell TN, Zandi KS, Miller S, Coe JW. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metabolism and Disposition 2006; 34(1)121–130
   PubMed Web of Science ®Google Scholar
• Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicology and Applied Pharmacology 2004; 199(3)193–209
   PubMed Web of Science ®Google Scholar
• Rodrigues AD, Rushmore TH. Cytochrome P450 pharmacogenetics in drug development: In vitro studies and clinical consequences. Current Drug Metabolism 2002; 3: 289–309
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 1994; 270(1)414–423
   PubMed Web of Science ®Google Scholar
• Shiraga T, Tozuka Z, Ishimura R, Kawamura A, Kagayama A. Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biological and Pharmaceutical Bulletin 2005; 28(1)124–129
   PubMed Web of Science ®Google Scholar
• Singh SS. Preclinical pharmacokinetics: An approach towards safer and efficacious drugs. Current Drug Metabolism 2006; 7(2)165–182
   PubMed Web of Science ®Google Scholar
• Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annual Review of Pharmacology and Toxicology 1998; 38: 389–430
   PubMed Web of Science ®Google Scholar
• Washio T, Arisawa H, Kohsaka K, Yasuda H. Identification of human drug-metabolizing enzymes involved in the metabolism of SNI-2011. Biological and Pharmaceutical Bulletin 2001; 24(11)1263–1266
   PubMed Web of Science ®Google Scholar